SSRI apathy
SSRI apathy is the flat, can't-be-bothered state that can set in while you keep taking an SSRI: drive drops and interest goes. Reviews describe it as linked to dose and reversible. Because loss of interest is also a symptom of depression, the two can be hard to tell apart, which makes it something to raise with your prescriber rather than live with. Emotional blunting is the related term for feelings that come through muted.
Also called: SSRI-induced apathy syndrome, SSRI-induced indifference.
Written by Alena Kozlova, PhD, from published studies and prescribing information.
Definition medically reviewed by Dr. Jason Tan, Consultant Psychiatrist, on November 11, 2026, this definition only. Next review: November 11, 2027.
What is SSRI apathy?
It shows as less drive, less interest in what used to pull at you, and feelings that arrive dulled. The onset is insidious rather than sudden, it comes on medication you have been taking for a while, and the reviews describe it as more likely on higher doses and as easing when the dose comes down. A 2023 systematic review of 50 papers in Acta Neuropsychiatrica found that apathy on antidepressants appears independently of the diagnosis, the age of the patient and how well the treatment is working, that it is dose dependent and reversible, and that dose reduction is the main strategy prescribers use.
The older papers said much the same from much less. A 2004 review in the Journal of Psychiatric Practice calls it an amotivational, or apathy, syndrome, notes that it is dose-dependent and reversible, and rests on twelve case reports and one open-label trial. A 2010 paper in Psychiatry (Edgmont) describes complete resolution of symptoms once the drug behind them is stopped. Both make the same practical point: it often goes unrecognized, by patients as much as by clinicians.
Emotional blunting is treated in the literature as a separate thing, frequently described, in the words of the 2010 paper, as a separate entity. Its authors proposed one name for both, SSRI-induced indifference, because indifference is what they share.
US labels name apathy rarely. The Celexa label lists it as a frequent psychiatric adverse reaction, which on that label means reported in at least 1 in 100 patients before approval. The Lexapro label lists apathy among the psychiatric reactions reported after the drug reached the market, where no frequency is attached. Neither names emotional blunting, so many people meet the experience before they meet a word for it.
Is it the SSRI or the depression?
Both, by the survey data, with the caveat that the surveys asked about emotional blunting on antidepressants in general rather than apathy on an SSRI. A 2017 survey in the Journal of Affective Disorders asked 669 depressed patients on treatment and 150 recovered controls about emotional side effects. Emotional blunting was reported by 46% of the treated patients, 52% of men and 44% of women, and blunting scores tracked depression scores. The authors conclude that emotional blunting cannot be described simply as a side-effect of antidepressants, but also as a symptom of depression.
Patients split the same way when asked directly. A 2022 survey put the question to 752 people in Brazil, Canada and Spain who were taking an antidepressant and had felt blunted in the previous six weeks: 56% put it down to the depression and 45% to their antidepressant, and the two run past 100% because people could name both. In the same group, 39% were considering stopping their antidepressant, or had already stopped, because of emotion-related side effects. That is 39% of people who already feel blunted rather than of everyone on a medication, and it is the reason to say it out loud: apathy nobody discusses often ends in a quiet stop.
What can you do about SSRI apathy?
Take it to your prescriber, because every option runs through them. The 2010 paper lists the three they weigh: lower the SSRI dose, add a second medication, or move off the SSRI to an antidepressant that is not a selective serotonin reuptake inhibitor. The 2023 review found dose reduction to be the usual first move. Which one fits depends on how well the medication is holding your depression, so it is a trade-off to make together rather than alone.
Stopping on your own is the move that backfires. MedlinePlus says not to stop escitalopram without talking to your doctor, that your doctor will probably decrease your dose gradually, and that a sudden stop can bring mood changes, irritability, agitation, nausea, dizziness, tingling in the hands or feet, anxiety, headache and sleep problems. NIMH says the same about prescribed medication in general, even when you are feeling better.
What to do
Keep a short daily note on your mood and energy, and on whether anything felt good that day, next to your dose. Two weeks of that answers the first question your prescriber will ask: did this start when the dose changed, or was it there before the medication? Then ask whether this is expected on your dose, what a lower dose or a different antidepressant would mean for you, and when the two of you would look at the result. If your mood drops, tell your prescriber without waiting for your next appointment. If you're having thoughts of harming yourself, contact emergency services or a crisis line straight away. In the US, call or text 988. In the UK, call Samaritans on 116 123. Elsewhere, call your local emergency number.
Read the guide to emotional blunting
How withClaro helps
- Log mood and energy next to each dose
- See whether it began with a dose change
- Share a PDF report with your prescriber
Get the withClaro app on the App Store
Related terms
Sources
- Barnhart WJ, Makela EH, Latocha MJ. Selective serotonin reuptake inhibitor-induced apathy syndrome: a clinical review. Journal of Psychiatric Practice, 2004.
- Sansone RA, Sansone LA. SSRI-induced indifference. Psychiatry (Edgmont), 2010.
- Masdrakis VG, Markianos M, Baldwin DS. Apathy associated with antidepressant drugs: a systematic review. Acta Neuropsychiatrica, 2023.
- Goodwin GM, Price J, De Bodinat C, Laredo J. Emotional blunting with antidepressant treatments: a survey among depressed patients. Journal of Affective Disorders, 2017.
- Christensen MC, Ren H, Fagiolini A. Emotional blunting in patients with depression. Part I: clinical characteristics. Annals of General Psychiatry, 2022.
- U.S. Food and Drug Administration. Celexa (citalopram): prescribing information. FDA / DailyMed, 2023.
- U.S. Food and Drug Administration. Lexapro (escitalopram) tablets and oral solution: prescribing information. FDA / DailyMed, 2026.
- U.S. National Library of Medicine. Escitalopram. MedlinePlus, 2025.
- National Institute of Mental Health (NIMH). Mental Health Medications. NIMH, 2024.
All glossary terms